Peptides for Libido: A Comprehensive Guide for Men and Women

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Low libido has multiple causes: hormonal (low testosterone, estrogen imbalance), neurological (dopamine/serotonin imbalance), psychological (stress, depression), and vascular. PT-141 addresses the neurological component centrally. Testosterone optimization addresses the hormonal component. BPC-157 may improve vascular function. A comprehensive approach addresses all contributing factors.

The Multifactorial Nature of Libido

Sexual desire is one of the most complex and multifactorial aspects of human physiology, involving the interplay of hormones, neurotransmitters, vascular function, psychological factors, and relationship dynamics. This complexity explains why single-intervention approaches to low libido often fail — effective treatment requires identifying and addressing all contributing factors simultaneously.

Hormonal Foundations

Testosterone is the primary driver of libido in both men and women. In men, testosterone levels below 400–500 ng/dL are commonly associated with reduced libido, and TRT consistently improves sexual desire in hypogonadal men. In women, testosterone levels decline significantly during the menopause transition and with age, and testosterone replacement at physiological doses improves libido in postmenopausal women. Estrogen also plays a role in female libido — both too little (causing vaginal dryness and discomfort) and too much (causing libido suppression) can impair sexual desire.

PT-141: Central Neurological Stimulation

PT-141 (bremelanotide) addresses the neurological component of libido by activating melanocortin receptors in the hypothalamus and limbic system. This central mechanism makes it effective for libido disorders that have a neurological component — including HSDD in women (FDA-approved) and low libido in men (off-label). PT-141 works regardless of hormonal status, making it useful as an adjunct to hormonal optimization or as a standalone intervention when hormonal levels are adequate. Typical dosing: 1–2 mg subcutaneously 1–2 hours before sexual activity.

Dopamine and Serotonin Balance

Dopamine drives sexual motivation and desire, while serotonin tends to inhibit it. This explains why SSRIs (which increase serotonin) commonly cause sexual dysfunction, and why dopaminergic interventions (including PT-141's indirect dopaminergic effects) can improve libido. Peptides that support dopamine function (Semax, which upregulates BDNF and dopamine) may complement PT-141 for libido enhancement.

Practical Protocol

A comprehensive libido optimization protocol might include: hormonal optimization (TRT for men with low T, testosterone + estrogen for postmenopausal women), PT-141 (1–2 mg as needed), BPC-157 (for vascular support), and psychological support if needed. Addressing sleep, stress, and relationship factors is equally important.